Switch theme
Sign up to access all valuation multiples
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.
2017
651
LTM Revenue $156M
LTM EBITDA -$90.6M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Everest Medicines has a last 12-month revenue (LTM) of $156M and a last 12-month EBITDA of -$90.6M.
In the most recent fiscal year, Everest Medicines achieved revenue of $90.2M and an EBITDA of -$113M.
Everest Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Everest Medicines valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $156M | XXX | $90.2M | XXX | XXX | XXX |
| Gross Profit | $117M | XXX | $67.2M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | -$90.6M | XXX | -$113M | XXX | XXX | XXX |
| EBITDA Margin | -58% | XXX | -125% | XXX | XXX | XXX |
| EBIT | -$106M | XXX | -$94.9M | XXX | XXX | XXX |
| EBIT Margin | -68% | XXX | -105% | XXX | XXX | XXX |
| Net Profit | -$114M | XXX | -$133M | XXX | XXX | XXX |
| Net Margin | -73% | XXX | -147% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Everest Medicines's stock price is HKD 44 (or $6).
Everest Medicines has current market cap of HKD 14.3B (or $1.8B), and EV of HKD 13.2B (or $1.7B).
See Everest Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.8B | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Everest Medicines has market cap of $1.8B and EV of $1.7B.
Everest Medicines's trades at 18.6x EV/Revenue multiple, and -14.9x EV/EBITDA.
Equity research analysts estimate Everest Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Everest Medicines has a P/E ratio of -17.4x.
See valuation multiples for Everest Medicines and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 11.7x | XXX | 18.6x | XXX | XXX | XXX |
| EV/EBITDA | -20.2x | XXX | -14.9x | XXX | XXX | XXX |
| EV/EBIT | -17.2x | XXX | -17.7x | XXX | XXX | XXX |
| EV/Gross Profit | 15.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.4x | XXX | -13.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEverest Medicines's last 12 month revenue growth is 85%
Everest Medicines's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Everest Medicines's rule of 40 is -506% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Everest Medicines's rule of X is 155% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Everest Medicines and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 85% | XXX | 96% | XXX | XXX | XXX |
| EBITDA Margin | -58% | XXX | -125% | XXX | XXX | XXX |
| EBITDA Growth | -94% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -506% | XXX | -40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 155% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 180% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Everest Medicines acquired XXX companies to date.
Last acquisition by Everest Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Everest Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Everest Medicines founded? | Everest Medicines was founded in 2017. |
| Where is Everest Medicines headquartered? | Everest Medicines is headquartered in Hong Kong. |
| How many employees does Everest Medicines have? | As of today, Everest Medicines has 651 employees. |
| Who is the CEO of Everest Medicines? | Everest Medicines's CEO is Mr. Yongqing Luo. |
| Is Everest Medicines publicy listed? | Yes, Everest Medicines is a public company listed on HKG. |
| What is the stock symbol of Everest Medicines? | Everest Medicines trades under 01952 ticker. |
| When did Everest Medicines go public? | Everest Medicines went public in 2020. |
| Who are competitors of Everest Medicines? | Similar companies to Everest Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Everest Medicines? | Everest Medicines's current market cap is $1.8B |
| What is the current revenue of Everest Medicines? | Everest Medicines's last 12 months revenue is $156M. |
| What is the current revenue growth of Everest Medicines? | Everest Medicines revenue growth (NTM/LTM) is 85%. |
| What is the current EV/Revenue multiple of Everest Medicines? | Current revenue multiple of Everest Medicines is 11.7x. |
| Is Everest Medicines profitable? | Yes, Everest Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Everest Medicines? | Everest Medicines's last 12 months EBITDA is -$90.6M. |
| What is Everest Medicines's EBITDA margin? | Everest Medicines's last 12 months EBITDA margin is -58%. |
| What is the current EV/EBITDA multiple of Everest Medicines? | Current EBITDA multiple of Everest Medicines is -20.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
